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Abstract
Purpose [S-methyl-11C]-L-methionine ([11C]MET) uptake in
the pancreas might be a central indicator of beta cell function.
Since gastric emptyingwas recently shown to influence glycemic
control in subjects after pancreaticoduodenectomy (PD, the sur-
gical treatment of neoplasms of the pancreas head), we looked
for imaginable relationships between gastric emptying, pre- and
postprandial insulin concentrations, and [11C]MET uptake.
Methods Nineteen tumor-free survivors after PD (age mean ±
SD: 61 ± 8.7 yrs.; 10 male, 9 female) and 10 healthy controls
(age: 27 ± 8.7 yrs.; 7 male, 3 female) were given a mixed test
meal. One gram of paracetamol was ingested with the meal to
evaluate the speed of gastric emptying. Insulin, glucose, and
paracetamol plasma concentrations were measured before and
over 180 minutes after ingestion. Beta cell function was calcu-
lated from fasting glucose and insulin plasma concentrations.
Simultaneously, 800 MBq of [11C]MET were administered and
the activity (maximum tissue standardized uptake values
[SUVmax]) over the pancreaswasmeasured at 15, 30, and60mi-
nutes after injection. Total integrated SUVmax (area under the
curve [AUC]) and incremental SUVmax were calculated.
Results The uptake of [11C]MET in the pancreas was signifi-
cantly higher (p< 0.0001) in controls compared to the PD group.
Gastric emptying was significantly slower in controls compared
to pancreatectomy subjects (p < 0.0001). Paracetamol AUC30
correlated with the SUVmax increment between 15 and 30 mi-
nutes (R2 = 0.27, p = 0.0263), suggesting a relationship between
gastric emptying and the uptake of [11C]MET. Total integrated
SUVmax correlated with insulin AUC60 (R
2 = 0.66,p< 0.0001)
in patients after PD. Multivariate regression analysis revealed
insulin AUC60 and beta cell function, calculated from the fasting
insulin to glucose ratio, as independent predictors of 11C-methi-
onine uptake, i.e. total integrated SUVmax, in patients after PD
(R2 = 0.78, p < 0.0001).
Conclusion Postprandial [11C]MET uptake may represent
basal and postprandial beta cell function. The findings suggest
a possible usefulness of this imaging procedure for further
studying beta cell function.
Keywords [11C]Methionine . Positron emission
tomography . Pancreas . Gastric emptying . Insulin . Beta cell
function
Introduction
Positron emission tomography (PET) is widely used to measure
amino acid metabolism and protein synthesis rates in vivo.
[S-methyl-11C]-L-methionine ([11C]MET), a PET tracer,
radiolabeled with short-lived carbon-11 without any alteration
to the molecular structure, is an universal donor of transmethyl
reactions that participates in the synthesis of DNA and RNA.
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Methionine is mainly incorporated in the liver, brain, pancreas,
and in tumors, where its main metabolic pathway is protein in-
corporation [1, 2]. Comar et al. suggested the use of [11C]MET
PET imaging for the examination of the pancreas in 1976 [3].
Since then, various studies have addressed the relationship be-
tween tracer uptake, beta cell function, and exocrine pancreatic
function [2, 4–11]. Syrota et al. studied [11C]MET uptake and
protein incorporation in duodenal aspirate in patients with chron-
ic pancreatitis, and observed a diminished uptake and incorpora-
tion of the tracer. Tracer uptake and amylase output after secretin
stimulation were closely correlated [8, 9]. Similarly, Takasu et al.
found a close relationship between tracer uptake and the secretin-
induced volume of duodenal secretions aswell as its amylase and
HCO3
− content [10, 11].
Okazumi et al. [12] were the first to report a relationship be-
tween methionine uptake and the insulinogenic index, which is
the relationship between fasting insulin and glucose and closely
related to insulin resistance (IR). Recently, Otsuki et al. measured
[11C]MET uptake in type I diabetics, showing a lower tracer
uptake as compared to healthy controls. Moreover, in pancreas
transplantation, a relationship was found between tracer uptake in
the donor pancreas and the duration of insulin independence after
transplantation. The authors also suggested this nuclear medical
approach to evaluate prospective pancreas donors [5–7].
Neoplasms of the pancreas head are treated surgically by
pancreaticoduodenectomy (PD) which comprises the resection
of the pancreatic head, the duodenum and — in the Whipple
procedure — distal gastrectomy. The pancreatic remnant, bile
duct and stomach are then reconnected using a jejunal loop
[13, 14]. Diabetes and impaired glycemic control is an issue in
cancer of the pancreas, where new onset diabetes mellitus is
observed [15–17], that frequently recedes after PD, the cause of
which is not known [18]. The velocity of gastric emptying has
been shown to instigate glycemic control in subjects having un-
dergone PD [19]. Gastric emptying speed can be estimated by
assessing the pace of paracetamol absorption, because paraceta-
mol is not absorbed in the stomach. Its early postprandial plasma
concentrations (AUC30) therefore represent the speed of gastric
emptying [20, 21] a finding that has been validated by
scintigraphy [22].
[11C]MET uptake seems to be a central indicator of beta cell
function. Therefore, we looked for factors associated with the
postprandial uptake in PD. We focused on possible relationships
between gastric emptying, pre- and postprandial insulin concen-
trations, and [11C]MET uptake.
Materials and methods
Subjects
Nineteen tumor-free subjects after PD were chosen from the
Medical University of Vienna’s surgical out-patient clinic after
screening 81 patients for eligibility. Ten patients who had un-
dergone a Whipple procedure and nine after pylorus-
preserving PD (PPPD) were included. The underlying dis-
eases had been neoplasms of the pancreas in 17 and chronic
pancreatitis in two subjects. Cases with type I diabetes, renal
failure, or cardiovascular diseases (>NYHA I) were not in-
cluded. Patient characteristics and those of 10 healthy volun-
teers are listed in Table 1.
PET-CT imaging
[11C]MET was prepared on-site for a maximum of three con-
secutive patients [23]. When the subjects ingested the test meal,
they simultaneously received an intravenous (i.v.) injection of
800 MBq [11C]MET and underwent the first of three PET-CTs
after 15 minutes of accumulation. The process required three to
five minutes per image. To reduce radiation exposure, only one
primary CT scan was obtained to be fused with the subsequent
PETscans. To obtain the best possible imaging quality, subjects
remained in a supine position, moving as little as possible, until
the last scan was recorded. At 15, 30, and 60 minutes after
tracer application, PET scans were recorded.
The imaging was performed using an integrated PET/CT
camera (Biograph 64 with True Point, Siemens, Erlangen,
Germany) equipped with a full-ring dedicated PET scanner and
a 64-slice CT scanner. CT scans were acquired with a 0.6-mm
slice thickness and a rotational speed of 0.5 s/rotation, using a
tube voltage of 120 kV and a nominal current of 230 mA and
pitch of 0.8. CT images were reconstructed with the smoothing
Bstandard^ and the edge-enhancing Bbone^ algorithms.
The PET scanner was equipped with a 21.6-cm axial field
of view. Imaging time was three minutes per bed position.
Patients and controls were scanned over the abdomen region.
Images were reconstructed in a 168 × 168 matrix with a 5-
mm pixel size using a two-dimensional ordered subset, recon-
struction true X, four iterations, and a 21 subsets all-pass filter.
Attenuation correction was performed using the previously
obtained CT scan reconstructed with an extended field of
view. Images were processed with a smoothing filter assuming
Table 1 Characteristics of
patients after
pancreaticoduodenectomy (PD)
and healthy controls (median and
25/75 quantile)
PD Control p value
Age (years) 64 (56 – 67) 24 (23.8 – 26) <0.0001
Gender (M:F ratio) 1.11 2.33 n.s.
BMI (kg/m2) 22.8 (21.2 – 26.8) 23.7 (21.2 – 26.8) n.s.
Time since operation (months) 18 (8 – 62) - -
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a full-width at half maximum (FWHM) of 5 mm (with a post-
filter assuming a FWHM of 5 mm). After processing of stand-
alone CT and PET images, a fusion data set with a transaxial
slice thickness of 5 mm was assembled.
Calculations
The area under the curve (AUC) was calculated using the trap-
ezoid rule to retrieve integrated values of the measured param-
eters. Therefore, AUC over 30minutes (AUC30) was calculated
as plasma concentrations/activity at 0–30 minutes (C0-C30) and
AUC over 60 minutes (AUC60) of concentration/activity at 0–
60 minutes (C0-C60) after test meal ingestion: AUC30 = ((C0 +
C10)*10/2) + ((C10 + C20)*10/2) + ((C20 + C30)*10 /2) and
AUC60 = AUC30 + ((C30 + C60)*30/2). In the case of
[11C]MET uptake: AUC60 = (C15 + C30)*15/2 + ((C30 +
C60)*30/2). Delta represents the incremental growth over time
and is the difference between concentrations of a measured
parameter at two different time points.
Imaging analysis
Maximum tissue standardized uptake values (SUVmax) were
obtained manually, based on regions of interest over the pan-
creas and over the liver. The [11C]MET pancreas to liver ratio
(PLR) was calculated. Regions of interest were the body and
tail of the gland. Tracer uptake increments (delta-SUVmax)
were calculated between 15–30 and 15–60minutes. AUC60 of
SUVmax was calculated as a measure of total uptake.
Modeling analysis
The homeostasis model assessment (HOMA) was applied to
calculate beta cell function and insulin resistance. The formula
by Matthews et al. [24] is based on the physiological glucose
production of the liver and the resulting insulin output of the
beta cells of the pancreas, regulating blood sugar levels in a
fasting state. Therefore, fasting plasma insulin (FPI, mU/l) and
fasting plasma glucose (FPG, mmol/l) were used to calculate
beta cell function (%B) and insulin resistance (IR) with the
following formulas: HOMA1 - IR = (FPI x FPG)/22.5; and
HOMA1 - %B= (20 x FPI)/(FPG - 3.5).
Blood tests
After an overnight fast, an indwelling catheter was inserted
into the cubital vein and blood was sampled before the inges-
tion of a liquid test meal (described below), as well as 10, 20,
30, 60, 90, 120, 150, and 180 minutes thereafter for the mea-
surement of insulin, glucose, and paracetamol concentrations.
Blood samples were obtained alongside the [11C]MET PET-
CT scans.
Plasma glucose was measured by the glucose oxidase
method, and insulin concentrations as described previously
[25]. For the measurement of paracetamol, blood was collect-
ed in heparin-coated collection tubes. Acetaminophen was
extracted with ethyl acetate and derivatized with N-methyl-
N-(trimethylsilyl)trifluoroacetamide (MSTFA, Macherey &
Nagel, Düren, Germany). D4-Acetaminophen (LGC
Standards, Luckenwalde, Germany) was used as the internal
standard. The calibration range was from 1 to 50 microgram/
mL; the acetaminophen standard was obtained from Lipomed
(Arlesheim, Switzerland). Analyses were performed by gas
chromatography–mass spectrometry (Agilent) in the EI scan
mode.
Mixed test meal
All subjects ingested a liquid test meal after the fasting blood
samples had been obtained. The meal was made up of 200 mL
Fresubin Protein Energy© (Fresenius Kabi, Graz, Austria)
and 50 mL cream (36 % fat). This liquid meal of 250 mL
consisted of 26.5 g carbohydrates, 21.1 g proteins, 31.4 g
fat, and a total of 472 kcal [26]. The drink was ingested within
1 minute. One g of paracetamol was admixed to the meal.
Gastric emptying was estimated by calculating AUC30 from
serial measurements of plasma paracetamol concentrations
[20–22].
Statistics
Variables are presented in median, 25 %, and 75 % quantiles.
Using JMP version 9, comparisons between parameters were
carried out using the nonparametric Wilcoxon test and the
one-sided Fisher’s exact test. Univariate and multivariate
linear regression was applied where appropriate. A p value
< 0.05 was considered significant.
Results
[11C]MET uptake was significantly higher in controls com-
pared to patients, at any of the three time points of measure-
ment (Table 2). Within the groups, the uptake did not differ
between the time points (Fig. 1). In controls, one measurement
of [11C]MET was not possible due to technical problems. In
this subject, SUVmax AUC60 could not be calculated.
Paracetamol peak concentrations and AUC30 were signifi-
cantly higher after PD (Table 3, Fig. 2a). Glucose baseline,
peak concentrations, and AUC60 were higher in patients com-
pared to controls, whereas insulin concentrations did not differ
(Table 3, Fig. 2b, c). HOMA-derived beta cell function (%B)
was smaller in PD subjects compared to controls whereas IR
did not differ (Table 3). Due to problems in continuous blood
aspiration and one corrupted insulin measurement,
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paracetamol measurements were analyzable in 18 patients,
insulin concentrations in 17 patients, and glucose measure-
ments in 18 patients. Single insulin parameters of one control
were missing, in which case no insulin AUC60 could be
calculated.
In patients, putative factors associated with total integrated
SUVmax, such as BMI, age, insulin AUC60, %B, IR, and
paracetamol AUC30were evaluated by single linear regression
and tested for significance. Insulin AUC60(Fig. 3a), beta cell
function (Fig. 3b), and IR (Fig. 3c) correlated with SUV. The
increment of SUVmax between 15 and 30 minutes (delta-
SUVmax30) showed a weak correlation with gastric emptying
(Fig. 4).
Including controls in the analyses, age (Fig. 5a) correlated
inversely and %B (Fig. 5b) correlated with total integrated
SUVmax; other parameters were not significant.
In multivariate regression, integrated insulin (AUC60) and
beta cell function emerged as independent predictors of 11C-
methionine uptake, i.e., total integrated SUVmax (R2 = 0.78, p
value = <0.0001, Table 4) in patients after PD. Including con-
trols in multiple regression analysis, age and insulin AUC60
showed to be independent predictors of [11C]MET uptake
(R2 = 0.69, p value = <0.0001, Table 4), i.e. age replaced %B
when controls were included.
Discussion
PD subjects, both with or without pylorus preservation, had
higher paracetamol concentrations (AUC30) compared to con-
trols, suggesting more rapid gastric emptying in the PD pa-
tients regardless of pylorus preservation (PPPD). The higher
fasting glucose in the PD patients probably reflects the lower
steady-state beta cell function. The rapid postprandial rise of
plasma glucose can be explained by the more rapid gastric
emptying, a relationship that is also observed after operations
such as total or partial gastrectomy [27, 28]. The composition
of the test meal produced lower glucose concentrations com-
pared to an oral glucose tolerance test used earlier [19]. The
same test meal, however, in PD patients, at shorter intervals
Table 2 Pancreas/liver-ratio (PLR) and maximum tissue standardized
uptake values (SUVmax) of the pancreas after 15, 30, and 60 minutes,
total integrated-SUVmax at 15–60 minutes (AUC60), and delta-SUVmax
(15–30 and 15–60 minutes) in patients after PD and in controls (median
and 25/75 quantile)





0.61 (0.29 – 1.28)
0.68 (0.24 – 1.26)
0.61 (0.27 – 1.02)
2.27 (2.01 – 2.76)
2.51 (2.04 – 2.84)








8.55 (2.7 – 12.5)
10.05 (2.9 – 13.9)
8.65 (3.1 – 15.3)
25.38 (19.33 – 27.49)
24.95 (22.76 – 28.78)







0.70 (0.00 – 1.83)
0.91 (0.20 – 1.85)
1.77 (0.95 – 2.80)




60 432.75 (144.38 – 626.25 1159.88 (1001.74 – 1324.80) <0.0001
Fig. 1 Maximal standardized uptake values (SUVmax) 15, 30, and
60 minutes after [S-methyl-11C]-L-methionine application in PD
subjects (•, n = 19) and controls (°, n = 10; means and SD)
Table 3 Glucose, insulin, and paracetamol concentrations. Beta cell
function (%B) and insulin resistance (IR; median and 25/75 quantile)







11.9 (10 – 25.4)
90 (10 – 127.5)
217.7 (128.9 – 367.8)
7.7 (6.8 – 11.4)
135 (112.5 - 150)









5.28 (2.9 – 8.82)
33.2 (22.1 – 74.45)
1067.7 (678.2 –
2550.58)
8.67 (5.5 – 10.7)











96.5 (85.3 – 110.8)
157.5 (132.3 – 171)
8005 (6025 – 8475)
82 (74.25 – 85)
97 (92 – 107.75)







59.2 (25.77 – 109.22)
1.05 (0.81 – 2.37)
180 (102.76 – 243.96)
1.8 (1.06 – 2.06)
0.0020
n.s.
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since operation than ours, showed a considerably lower in-
crease of paracetamol, suggesting that the speed of gastric
emptying recovers with time after the operation [26].
Compared to controls, the patients exhibited an impaired
glycemic control: their baseline glucose concentrations were
higher and baseline beta cell function was lower. The integrat-
ed glucose concentrations during the first hour (AUC60), when
the [11C]MET uptake was measured, were twice the value of
those in controls. Since our test meal contained no glucose and
only 26 g carbohydrates compared with the 75 g glucose used
in the oral glucose test by Harmuth et al. [19], we consider this
difference to be a sign of impaired glycemic control rather
than the consequence of rapid gastric emptying. The later peak
of insulin concentrations in controls may also be explained by
the slower gastric emptying. The failure of the PD patients’
early postprandial insulin to exceed that of controls is conceiv-
ably one of the sequelae of inadequate insulin production ca-
pability, a possible sequel of resection and advanced age.
The lower SUVmax in patients and the correlation between
[11C]MET uptake and early insulin concentrations suggest
that the tracer uptake represents insulin production.
Moreover, the preprandial baseline beta cell function also cor-
relates with SUVmax. Differences in age might contribute to
the difference of tracer uptake and insulin production between
controls and PD subjects [29].
In the PD patients, the increase in SUVmax between 15 and
30 minutes correlated with paracetamol AUC30. It is well
known that rapid gastric emptying enhances the release of
incretins, such as GLP-1, which, in combination with glucose,
is a potent stimulus of insulin release [30]. This likely explains
the relationship between tracer uptake and gastric emptying.
The association of methionine uptake and insulin production
is further underlined by the results of multiple regression anal-
ysis, where basal beta cell function and first-hour integrated
insulin concentrations were both independently correlated
with SUVmax AUC60.
In earlier reports, the uptake of methionine has been
discussed in the context of exocrine pancreatic function [9,
11]. Syrota and Takasu et al. evaluated [11C]MET uptake of
the pancreas in patients suffering from chronic pancreatitis
and alcohol disease, showing a relationship between tracer
accumulation and enzyme output of the pancreas as well as
tracer incorporation into digestive enzymes. Chronic pancre-
atitis is a destructive disease that involves the exo- and endo-
crine pancreas; therefore, diabetes is a common complication
[31]. While the authors assume [11C]MET PET as an appro-
priate tool for examining the exocrine gland, diabetes and
impaired endocrine function is hardly addressed in these pub-
lications. However, beta cell function is probably also
Fig. 2 Time course of paracetamol (a, n = 18), glucose (b, n = 18), and
insulin (c, n = 17) concentrations after the test meal in patients after PD (•)
and in controls (n = 10,°; means and SD)
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represented by methionine accumulation in the pancreas. In
patients after PD, the exocrine pancreatic function is signifi-
cantly impaired [32]. In our population, correlations between
beta cell function and total methionine uptake were
significant. We found a close association between uptake
and basal as well as postprandial beta cell function, but we
Fig. 3 Relationship between total integrated SUVmax (AUC60) and
insulin AUC60 (a), beta cell function (b), and IR (c) in patients after PD
(•, n = 17)
Fig. 4 Gastric emptying (integrated paracetamol [AUC30]) and
incremental SUV between 15 and 30 minutes post-meal in patients after
PD (•, n = 18)
Fig. 5 Relationship between total integrated SUVmax (AUC60), age (a,
n = 19) and beta cell function (b, n = 17) in patients after PD (•) and in
controls (°, n = 9)
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cannot determine the relative contribution of the exocrine
function to the measured uptake. As already mentioned above,
Otsuki et al. identified a reduced uptake of methionine in
pancreata of patients with type I diabetes. They also showed
that after pancreas transplantation, the tracer uptake in the
donor pancreas predicted the long-term efficacy of the trans-
plant to maintain glycemic control [2, 5–7], stressing the sig-
nificance of beta cell function for the uptake.
Not differentiating between exo- and endocrine pancreatic
function, Kono et al. [4] measured methionine uptake before
and after operation in patients undergoing distal pancreatecto-
my and in PD cases. The fasting methionine uptake in the
remaining pancreas was lower in the PD group, the cause of
which is unknown. The lower methionine uptake after PD,
compared to left-sided pancreas resection, might be explained
by the lower IR as a result of malabsorption and ensuing
malnutrition after PD [33, 34]. Conceivably, the lower uptake
in PD patients could also be a sign of impaired stimulation of
the exocrine pancreas after duodenal resection and reduced
release of hormones that stimulate the exocrine gland, such
as cholecystokinin [32].
Unfortunately, our results do not allow us to determine the
relative impact of exocrine and endocrine function, and further
studies with simultaneous measurement of both functions
seem to be desirable to clarify the correlation between
[11C]MET uptake and insulin production. One major limita-
tion of this study was the younger control group of healthy
subjects, which prevented us to assess the impact of age on the
measurements.
This study, the first to look at [11C]MET uptake in combi-
nation with plasma insulin concentrations during a test meal,
illustrates the relationship between tracer uptake and insulin
production. The findings suggest that this imaging procedure
is an appropriate tool to further study beta cell function.
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